213 related articles for article (PubMed ID: 31710149)
1. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent.
Barkholt TØ; Webber B; Holm NR; Ormiston JA
Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149
[TBL] [Abstract][Full Text] [Related]
2. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition).
Ormiston JA; Webber B; Ubod B; Darremont O; Webster MW
EuroIntervention; 2015 May; 11(1):60-7. PubMed ID: 25680225
[TBL] [Abstract][Full Text] [Related]
3. Effect of non-compliant balloon postdilatation on magnesium-based bioresorbable vascular scaffolds.
Blachutzik F; Achenbach S; Tröbs M; Marwan M; Weissner M; Nef H; Schlundt C
Catheter Cardiovasc Interv; 2019 Feb; 93(2):202-207. PubMed ID: 30196573
[TBL] [Abstract][Full Text] [Related]
4. Sequential Proximal Optimizing Technique in Provisional Bifurcation Stenting With Everolimus-Eluting Bioresorbable Vascular Scaffold: Fractal Coronary Bifurcation Bench for Comparative Test Between Absorb and XIENCE Xpedition.
Derimay F; Souteyrand G; Motreff P; Guerin P; Pilet P; Ohayon J; Darremont O; Rioufol G; Finet G
JACC Cardiovasc Interv; 2016 Jul; 9(13):1397-406. PubMed ID: 27388830
[TBL] [Abstract][Full Text] [Related]
5. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
Džavík V; Colombo A
JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
[TBL] [Abstract][Full Text] [Related]
6. In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond.
Schmidt W; Behrens P; Brandt-Wunderlich C; Siewert S; Grabow N; Schmitz KP
Cardiovasc Revasc Med; 2016 Sep; 17(6):375-83. PubMed ID: 27266902
[TBL] [Abstract][Full Text] [Related]
7. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Side-Branch Dilation Techniques After Resorbable Magnesium Scaffold Implantation: A Bench Study.
de Pommereau A; Mogi S; de Hemptinne Q; Adjedj J; Varenne O; Picard F
J Invasive Cardiol; 2019 Aug; 31(8):E249-E255. PubMed ID: 31368896
[TBL] [Abstract][Full Text] [Related]
10. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
[TBL] [Abstract][Full Text] [Related]
12. Magnesium 2000 postmarket evaluation: Guideline adherence and intraprocedural performance of a sirolimus-eluting resorbable magnesium scaffold.
Wlodarczak A; Garcia LAI; Karjalainen PP; Komócsi A; Pisano F; Richter S; Lanocha M; Rumoroso JR; Leung KF
Cardiovasc Revasc Med; 2019 Dec; 20(12):1140-1145. PubMed ID: 30833209
[TBL] [Abstract][Full Text] [Related]
13. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies.
Ormiston JA; Webber B; Ubod B; Webster MW; White J
EuroIntervention; 2015 Feb; 10(10):1169-77. PubMed ID: 24835848
[TBL] [Abstract][Full Text] [Related]
14. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
[TBL] [Abstract][Full Text] [Related]
15. Acute Mechanical Performance of Magmaris vs. DESolve Bioresorbable Scaffolds in a Real-World Scenario.
Boeder NF; Dörr O; Koepp T; Blachutzik F; Achenbach S; Elsässer A; Hamm CW; Nef HM
Front Cardiovasc Med; 2021; 8():696287. PubMed ID: 34195239
[No Abstract] [Full Text] [Related]
16. Bioresorbable scaffolds on the bench.
Ormiston J; Motreff P; Darremont O; Webber B; Guerin P; Webster M
EuroIntervention; 2015; 11 Suppl V():V166-9. PubMed ID: 25983158
[TBL] [Abstract][Full Text] [Related]
17. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.
Waksman R; Zumstein P; Pritsch M; Wittchow E; Haude M; Lapointe-Corriveau C; Leclerc G; Joner M
EuroIntervention; 2017 Jul; 13(4):440-449. PubMed ID: 28262623
[TBL] [Abstract][Full Text] [Related]
18. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100.
Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM
Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164
[TBL] [Abstract][Full Text] [Related]
19. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
20. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
